Yifan Pharmaceutical Hits Day Low of CNY 9.31 Amid Price Pressure

Yifan Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 3.61% to reach an intraday low of CNY 9.31. This performance contrasts sharply with the China Shanghai Composite, which saw a modest gain of 0.5% on the same day. Over the past week, Yifan's stock has decreased by 6.59%, and its performance over the last month shows a significant drop of 10.78%. Year-to-date, the stock has declined by 21.82%, while its one-year performance reflects a substantial decrease of 28.02%. The long-term outlook is similarly concerning, with a three-year decline of 35.96% and a five-year drop of 45.8%. Financial metrics indicate challenges for Yifan Pharmaceutical, including a low Return on Capital Employed (ROCE) of 2.72% and a Return on Equity (ROE) of 3.72%. The company has also reported a net profit decline of 29.96% in its latest half-year results. Despite being net-debt free, the company has struggled with stagnant sales growth and a high valuation relative to its profitability.